Exelixis, Inc. (NASDAQ:EXEL) Insider Sells $20,230.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) insider Patrick J. Haley sold 1,000 shares of Exelixis stock in a transaction on Monday, June 10th. The shares were sold at an average price of $20.23, for a total value of $20,230.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Patrick J. Haley also recently made the following trade(s):

  • On Friday, May 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $19.58, for a total value of $19,580.00.
  • On Wednesday, April 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $24.04, for a total value of $24,040.00.
  • On Tuesday, March 26th, Patrick J. Haley sold 2,700 shares of Exelixis stock. The shares were sold at an average price of $23.47, for a total value of $63,369.00.
  • On Thursday, March 14th, Patrick J. Haley sold 2,000 shares of Exelixis stock. The shares were sold at an average price of $25.00, for a total value of $50,000.00.

Shares of EXEL traded down $0.09 during trading hours on Friday, hitting $19.82. The stock had a trading volume of 39,063 shares, compared to its average volume of 2,327,762. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.56 and a quick ratio of 7.48. Exelixis, Inc. has a 12 month low of $13.42 and a 12 month high of $25.31. The firm has a market capitalization of $6.01 billion, a P/E ratio of 13.86, a PEG ratio of 0.47 and a beta of 1.99.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.24 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.24. Exelixis had a return on equity of 37.21% and a net margin of 75.97%. The company had revenue of $215.49 million during the quarter, compared to analyst estimates of $206.06 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. Exelixis’s revenue was up .8% compared to the same quarter last year. Analysts expect that Exelixis, Inc. will post 0.92 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Exelixis by 1.0% during the first quarter. BlackRock Inc. now owns 30,875,633 shares of the biotechnology company’s stock valued at $734,839,000 after purchasing an additional 290,882 shares during the period. Vanguard Group Inc grew its holdings in Exelixis by 3.2% during the third quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after purchasing an additional 834,478 shares during the period. AQR Capital Management LLC grew its holdings in Exelixis by 46.4% during the first quarter. AQR Capital Management LLC now owns 15,852,556 shares of the biotechnology company’s stock valued at $377,291,000 after purchasing an additional 5,021,444 shares during the period. JPMorgan Chase & Co. grew its holdings in Exelixis by 10.1% during the first quarter. JPMorgan Chase & Co. now owns 9,938,985 shares of the biotechnology company’s stock valued at $236,548,000 after purchasing an additional 910,147 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Exelixis by 61.6% during the first quarter. Renaissance Technologies LLC now owns 9,565,273 shares of the biotechnology company’s stock valued at $227,653,000 after purchasing an additional 3,645,546 shares during the period. 78.27% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have issued reports on EXEL shares. Cowen reiterated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research note on Tuesday, April 23rd. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. Oppenheimer reiterated a “buy” rating on shares of Exelixis in a research note on Tuesday, March 19th. Morgan Stanley upgraded Exelixis from an “underweight” rating to an “equal weight” rating and set a $24.80 price target for the company in a research note on Monday, March 18th. Finally, ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $28.88.

COPYRIGHT VIOLATION WARNING: “Exelixis, Inc. (NASDAQ:EXEL) Insider Sells $20,230.00 in Stock” was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2019/06/14/exelixis-inc-nasdaqexel-insider-sells-20230-00-in-stock.html.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What is a short straddle?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.